

Glenmark monoclonal antibody trial

Mumbai, April 29

Glenmark Pharmaceuticals SA, a wholly owned Swiss subsidiary of Mumbai-based Glenmark Pharmaceuticals, has announced that its monoclonal antibody, involved in chronic pain, is entering human trials. In 2010, Glenmark gained an exclusive worldwide licence from Lay Line Genomics SpA In Italy, for anti-TrkA antibodies and their entire intellectual property portfolio in the TrkA field. The company said GBR 900 is the optimised anti-TrkA antibody emerging from this exclusive worldwide licence. Glenmark has now completed the Phase I trials enabling preclinical development programme for GBR 900, and has filed a Phase I clinical trial application with the UK's MHRA. GBR 900 is the first anti-TrkA monoclonal antibody to enter clinical development. OUR BUREAU

Clinical trial.